| Similar Articles |
|---|
 |
The Motley Fool
January 29, 2010
Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity.   |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
June 10, 2010
Brian Orelli |
Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday. |
The Motley Fool
June 4, 2009
Brian Orelli |
Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price. |
The Motley Fool
May 13, 2009
Brian Orelli |
Icahn's an Energizer Pit Bull He keeps going and doesn't let go. |
The Motley Fool
November 18, 2008
Brian Orelli |
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. |
The Motley Fool
February 6, 2009
Brian Orelli |
Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board. |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
August 5, 2008
Brian Lawler |
An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool
September 15, 2008
Brian Orelli |
Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company. |
The Motley Fool
April 8, 2010
Brian Orelli |
Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult. |
The Motley Fool
October 4, 2006
Brian Lawler |
Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool
June 15, 2010
Ryan McBride |
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week. |
The Motley Fool
June 19, 2008
Brian Orelli |
Live From Bio: Activist Investors Activist investors throw a fit and try to get management changes when they're not happy, like Carl Icahn has done with ImClone Systems and tried to do with Biogen Idec. As they become more common, how are companies dealing with them? |
The Motley Fool
May 29, 2008
Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
January 5, 2010
Brian Orelli |
Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out. |
The Motley Fool
April 16, 2009
Brian Orelli |
Icahn: Ludicrous and Arrogant Fun to read, but does he have the best intentions for long-term shareholders? |
The Motley Fool
July 23, 2008
Rick Aristotle Munarriz |
Icahn's Spotty Track Record Carl Icahn and Yahoo! have made nice, in advance of next week's meeting, but will the peace last? Or is the current calm just the eye of the hurricane? |
The Motley Fool
June 22, 2011 |
Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011. |
The Motley Fool
April 15, 2005
Tom Taulli |
Carl Icahn Strikes Again Energy and inorganic-chemical company Kerr-McGee and investor Icahn make peace. The market's happy, and Icahn's war chest just gets bigger. |
The Motley Fool
September 29, 2006
Brian Lawler |
ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree. |
The Motley Fool
September 21, 2006
Brian Lawler |
ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors. |
The Motley Fool
May 19, 2008
Brian Orelli |
What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase. |
The Motley Fool
June 8, 2010
Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
BusinessWeek
March 5, 2007
Ronald Grover |
Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola. |
The Motley Fool
December 13, 2007
Brian Lawler |
Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers. |
The Motley Fool
June 16, 2010
Ryan McBride |
Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors. |
The Motley Fool
September 24, 2008
Brian Lawler |
Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems. |
InternetNews
July 20, 2009 |
Icahn Pushing Again for Yahoo-Microsoft Deal Carl Icahn, the billionaire investor who made so much trouble for Yahoo last year, has spoken out in favor of a deal with Microsoft, which reportedly could be announced as early as this week. |
The Motley Fool
October 14, 2011
Travis Hoium |
Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day. |
The Motley Fool
September 1, 2009
Rick Aristotle Munarriz |
Icahn Handles the Truth at Yahoo! Carl Icahn has sold shares of struggling online giant Yahoo! in each of the past three trading days, enough to take his stake below 5%. |
The Motley Fool
October 25, 2006
Brian Lawler |
Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn. |
The Motley Fool
July 8, 2008
Rick Aristotle Munarriz |
Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!. |
The Motley Fool
February 17, 2010
Anders Bylund |
Who Is Icahn Selling To Now? Lionsgate is looking to buy the Miramax studio from Walt Disney in what looks like a good stylistic match. Will Carl Icahn turn the tables on that deal and coax a bid out of Disney? |
The Motley Fool
June 30, 2010
Ryan McBride |
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately. |
The Motley Fool
May 14, 2010
Ryan McBride |
Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back. |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
May 16, 2008
Mac Greer |
Fool Video: Icahn Bares His Teeth, Craig's Cyst, and 5 Stocks Approaching Greatness Can Craigslist delete eBay? Will Icahn deliver for Microsoft? These questions are discussed in this video. |
The Motley Fool
June 1, 2009
Brian Orelli |
Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what? |
The Motley Fool
November 23, 2004
Charly Travers |
Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it. |
The Motley Fool
May 28, 2009
Brian Orelli |
Best of Both Worlds Fresh blood on Amylin's Board of Directors should be able to offer a new opinion as to how things should change without disrupting the company's progress. |
The Motley Fool
September 15, 2011
Dawn Kawamoto |
Reshuffling Yahoo!'s Board: A New House of Cards? It may take an activist shareholder to bring about meaningful change. |
Search Engine Watch
August 6, 2008
Kevin Ryan |
Woohoo for Yahoo Even after the vote re-count, a majority of shareholders voted Yahoo's board in, and Carl Icahn settled for the right to propose two board seats and a spot for himself. At the end of the day, what's more important than rebuilding the Web's biggest brand? |
The Motley Fool
February 8, 2005
Tom Taulli |
Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. |
The Motley Fool
May 15, 2008
Rick Aristotle Munarriz |
Bored of Directors at Yahoo! Carl Icahn has Yahoo!'s board in his crosshairs. |
